Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment

被引:0
|
作者
Drobyski, WR
Majewski, D
Ozker, K
Hanson, G
机构
[1] Med Coll Wisconsin, Bone Marrow Transplant Program, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
来源
JOURNAL OF IMMUNOLOGY | 1998年 / 161卷 / 05期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The purpose of this study was to determine whether ex vivo anti-CD3 Ab-activated T cells behaved in a biologically similar manner as naive T cells with respect to causing graft-vs-host disease (GVHD) and facilitating engraftment after allogeneic marrow transplantation, This question was addressed using two well-defined MHC-incompatible murine models of GVHD (C57BL/6 (H-2(b))-->B10.BR (H-2(k))) and engraftment (C57BL/6 (H-2(b))-->AKR/J (H-2(k))). Transplantation with anti-CD3-activated T cells significantly reduced GVHD compared with that in animals transplanted with equivalent numbers of naive T cells. Protection from GVHD was not T cell subset dependent, as highly enriched populations of either activated CD4(+) or CD8(+) T cells caused less lethal GVHD than comparable numbers of purified naive CD4(+) or CD8(+) T cells. Transplantation with activated T cells also resulted in protection from LPS-mediated GVH lethality in unirradiated F-1 recipients. Analysis of immune recovery indicated that animals transplanted with activated T cells had thymic and splenic B cell reconstitution that compared favorably to that in non-GVHD control mice. When engraftment was analyzed, equivalent degrees of donor cell engraftment were observed when animals were transplanted with limiting numbers (5 x 10(5)) of naive vs activated B6 T cells. Further studies indicated that activated CD8(+) T cells were exclusively responsible for enhancing engraftment and that facilitation of engraftment was dependent upon the direct recognition of host MHC alloantigens. Collectively, these data demonstrate that transplantation,vith anti-CD3 Ab-activated T cells results in a reduction in GVHD, but these cells retain their ability to facilitate alloengraftment. The use of this approach in allogeneic marrow transplantation may represent an alternative strategy to mitigate GVHD without compromising engraftment.
引用
收藏
页码:2610 / 2619
页数:10
相关论文
共 50 条
  • [1] Ex vivo anti-CD3 antibody activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease (GVHD) but retain their ability to facilitate alloengraftment.
    Drobyski, WR
    Majewski, D
    Ozker, K
    Hanson, G
    BLOOD, 1997, 90 (10) : 1761 - 1761
  • [2] Anti-CD3ε F(ab′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
    Yu, XZ
    Bidwell, SJ
    Martin, PJ
    Anasetti, C
    JOURNAL OF IMMUNOLOGY, 2001, 166 (09): : 5835 - 5839
  • [3] Anti-CD3 F(AB′)2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens.
    Anasetti, C
    Bidwell, BJ
    Martin, PJ
    Xu, XZ
    BLOOD, 2000, 96 (11) : 582A - +
  • [4] Ex vivo-expanded donor T cells have a reduced ability to facilitate the engraftment of an allogeneic bone marrow graft as compared to fresh donor T cells.
    Perruche, S
    Angonin, R
    Ferrand, C
    Robinet, E
    Cohen, JL
    Klatzmann, D
    Hervé, P
    Tiberghien, P
    Saas, P
    BLOOD, 2001, 98 (11) : 381A - 382A
  • [5] TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH A NONMITOGENIC ANTI-CD3 MONOCLONAL-ANTIBODY
    ANASETTI, C
    MARTIN, PJ
    STORB, R
    APPELBAUM, FR
    BEATTY, PG
    DAVIS, J
    DONEY, K
    HILL, HF
    STEWART, P
    SULLIVAN, KM
    WITHERSPOON, RP
    THOMAS, ED
    HANSEN, JA
    TRANSPLANTATION, 1992, 54 (05) : 844 - 851
  • [6] MODULATION OF MURINE HOST-VERSUS-GRAFT DISEASE BY ANTI-CD3 MONOCLONAL-ANTIBODY
    WISSING, M
    MARCHANT, A
    MOSER, M
    FLAMAND, V
    LEO, O
    ABRAMOWICZ, D
    URBAIN, J
    GOLDMAN, M
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1991, 83 (02): : 333 - 337
  • [7] Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody
    Zhang, Chunyan
    Lou, Jingwei
    Li, Nainong
    Todorov, Ivan
    Lin, Chia-Lei
    Cao, Yu-An
    Contag, Christopher H.
    Kandeel, Fouad
    Forman, Stephen
    Zeng, Defu
    JOURNAL OF IMMUNOLOGY, 2007, 178 (02): : 838 - 850
  • [8] Graft facilitating doses of ex vivo activated γδ T cells do not cause lethal-murine graft-versus-host disease (GVHD) and thereby have a superior therapeutic index when compared to limiting numbers of naive αβ T cells.
    Drobyski, WR
    Majewski, D
    Hanson, G
    BLOOD, 1998, 92 (10) : 720A - 720A
  • [9] Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene
    Drobyski, WR
    Morse, HC
    Burns, WH
    Casper, JT
    Sandford, G
    BLOOD, 2001, 97 (08) : 2506 - 2513
  • [10] CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
    Blazar, BR
    Taylor, PA
    Noelle, RJ
    Vallera, DA
    JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03): : 473 - 482